GONORRHEA is still a major public health problem, despite the development of sulfonamides (1) and of penicillin (2,3). The appearance and wide dissemination of sulfonamide-resistant strains of gonococci during and shortly after the Second World War might well have reduced the physician to his former helplessness in the face of this disease had not penicillin become available during that period. There are, however, important limitations to the usefulness of penicillin. Not only have penicillin-resistant strains of gonococci appeared (4,5), but many patients are sensitive to this antibiotic (5,6). Fortunately, tetracycline is effective against gonococcal infection and already is widely used in the treatment of penicillin-sensitive patients (7). The use of broad-spectrum antibiotics can, however, disturb the internal ecology by permitting the overgrowth of nonsensitive organisms, including the yeastlike forms, such as Candida albicans (7-10). Therefore, it may be advisable to administer an antifungal agent prophylactically when a broad-spectrum antibiotic is given, especially if the antibiotic is administered in high dosage. It has been remarked, however, that the addition of such an agent adds nothing to the therapeutic effectiveness of tetracycline and introduces the possibilities of development of antibiotic-resistant strains of fungi and the further enhancement of overgrowth of potentially dangerous organisms. An orally administered formulation combining tetracycline and amphotericin B was used as the original treatment in a large number of patients with acute gonococcal urethritis seen in the principal venereal disease clinic in Philadelphia,, Pa. During a period of 4 months, all male patients, aged 18 years and over, admit,ted to the clinic were offered a choice of the conventional intramuscular treatment with penicillin or a combined oral formulation of tet,racycline and amphoitericin B for their acute gonorrheal infections. Those who chose the oral therapy were screened for their ca,seholding potential by the full-time public health nurse assigned to the study. Of these patients, 234, 9 white and 225 nonwhite, were accepted for the study. However, in pretreatment diagnosis, 22 patients had negative cultures or smears. Each of the remaining 212 patients consumed in the presence of the nurse eight capsules constituting a single oral dose of 2 grams tetracycline, and each patient wa's instructed to return to the clinic for 3 consecutive weeks for post-treatment observation. One hundred patients returned to the clinic for 3 weeks, 50 for 2 weeks, 41 for 1 week, and 21 patients were lost to followup. The sole medication used was a combined formulation of phosphate potentiated tetracycline and the antimycotic agent amphotericin B. Dosage was determined by the tetracycline content of the medication. The modality used was a capsule containing tetracycline phosphate complex equivalent to 250 mg. tetracycline hydrochloride and 50 mg. amphotericin B. Eight such capsules constituted the single oral dose of 2 gm. tetracycline given to each patient. Detailed laboratory studies, performed for The authors are with the Philadelphia Department of Public Health. Dr. Lentz is chief, and Dr. MacVicar is assistant chief, section of venereal disease control, community health services. Mr. Beilstein is assistant director, public health laboratory.